Live- In Person Arizona, Meeting

1.0 CME/NCPD Credit
Click Here to complete the pre-assessment

This regional series consists of three individual activities (2 virtual and 1 live in-person) tailored to the educational needs of rural U.S.-based clinicians who treat patients with T2D and obesity and practice in geographic areas with a greater prevalence of the disease. Part 3 of this Community Collective series is designed to facilitate networking and collaborative consultation among local clinicians and practicing clinicians who practice in your area.

Pre-Assessment

Please enable JavaScript in your browser to complete this form.
Name
Profession
Speciality
1. According to the 2023 guidelines by the American Diabetes Association and the European Association for the Study of Diabetes, in most adults with T2D and a life expectancy of 10 years or more what should be the standard approach in management of a patient’s diabetes?
2. While A1c has long been considered the gold-standard for measuring T2D levels it is subject to various limitations, one of which includes:
3. Ms. Shields is a 62-year-old female with an A1c of 8.1% (blood glucose of 185 mg/dL) and a BMI of 33 kg/m2. She recently moved in with her daughter who resides in Pella, Iowa (population ~10,500) and now works at a local grocery store, which does not provide her with insurance. Time spent being active is only when interacting with her grandchildren. She has struggled with T2D and overweight/obesity for much of her life and is interested taking a GLP-1 RA or GIP/GLP-1 RA to manage both but is particularly interested in the weight loss aspect of these medications. Through shared decision-making and given that she is an eligible patient to receive one of these medications, what would likely be the greatest barrier given her circumstances?
4. Based on results from the SURPASS and SURMOUNT clinical trials, which statement is correct?
5. Mr. Rodriguez is eligible for treatment with a GLP-1 RA or GIP/GLP-1 RA for both T2D and obesity. What counseling and education would you provide to him so that he can make an informed decision about medication selection:
6. Ms. Gilmore is a 41-year-old female who presents in clinic after beginning a GLP-1 RA or GIP/GLP-1 RA. At baseline her A1c was 8.6% and today she presents with an A1c of 7.3% (blood glucose of 162 mg/dL) and a BMI of 25 kg/m2. She states that she has been working hard to maintain a healthy diet and exercise for at least 30 minutes per day and has been pleased with the drop in her A1c as a result. She has restarted playing golf with her husband now that she feels less fatigue daily. She is happy with her current medication regimen for both the management of the T2D and her weight. Which of the following is not a patient-reported outcome?
Go to Event Site
Scroll to Top